# Dapagliflozin in PRESERVED Ejection Fraction Heart Failure

> **NCT03030235** · PHASE4 · COMPLETED · sponsor: **Saint Luke's Health System** · enrollment: 324 (actual)

## Conditions studied

- Chronic Heart Failure With Preserved Systolic Function

## Interventions

- **DRUG:** Dapagliflozin 10Mg Oral Tablet
- **DRUG:** Dapagliflozin matching placebo

## Key facts

- **NCT ID:** NCT03030235
- **Lead sponsor:** Saint Luke's Health System
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-01
- **Primary completion:** 2021-08-13
- **Final completion:** 2021-08-13
- **Target enrollment:** 324 (ACTUAL)
- **Last updated:** 2022-10-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03030235

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03030235, "Dapagliflozin in PRESERVED Ejection Fraction Heart Failure". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03030235. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*